Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 767551 for mild to moderate non-hospitalized COVID-19
NL-OMON51124Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lomtegovimab in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Primary endpoint Phase II and Primary endpoint Phase III. Planned start Mar 2021; status: withdrawn.
02
Drugs
lomtegovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51124.